Cargando…
The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
BACKGROUND: Thymosin α1 (Tα1) as immunomodulatory treatment is supposed to be beneficial for the sepsis patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and the poor study design, the persuasive power of the single clinical studies is weak....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025565/ https://www.ncbi.nlm.nih.gov/pubmed/27633969 http://dx.doi.org/10.1186/s12879-016-1823-5 |